[Home] [Reports] [Startups] [ONLINE STORE] [site map]


Order report

The report below has been superceded by the newest report on Tissue Engineering, Cell Therapy & Transplantation. Click here.

Tissue Engineering and Cell Therapy Markets, 2002-2012

Report S501

· 247 pages   · 28 Exhibits   · 100 Company Profiles   · Pub. Date June 2002   · Report #S501


This report focuses on the use of mammalian cells for therapeutic benefit in medicine. We review the cell-based therapeutic technologies being progressed by over eighty companies. The products they pursue are targeting most of the major causes of death and disease, and offer permanent solutions where other technologies offer only temporary or symptomatic relief. We have not included technologies based on materials or pharmaceutical agents alone, but have provided a comprehensive overview of all cell-based technologies that are likely to progress to market within the next decade.

Table of Contents

Executive Summary

Section 1:        Introduction

1.1       Definition

1.2       Development Challenges

1.3       Market Expectations

1.4       Sales from Tissue Engineered Products

1.5       Forecast for Cell-Based Tissue Engineering

1.6       Unmet Clinical Need

1.7       Developing Tissue-Engineered Products

1.7.1          Culturing Cells

1.7.2          Cell Delivery

1.7.3          Bioengineering Cells and Tissues

1.7.4          Autologous, Allogeneic, and Xenogeneic Products

1.8       Timescales

1.8.1          Sector Challenges

1.8.2          Regulatory, Cost Effectiveness and Clinical       Regulatory       Cost effectiveness       Clinical

1.9       Competition Intensity

1.9.1          Industry focus

1.9.2          Investment levels

1.9.3          Investor Returns

Section 2:        Caseload for cell-based tissue engineering

2.1       Overview

2.2       Cardiovascular

2.2.1          Introduction

2.2.2          Coronary Heart Disease

2.2.3          Myocardial Infarction

2.2.4          Congestive Heart failure

2.2.5          Dysfunctional Heart Valves

2.2.6          Peripheral Vascular Disorders

2.2.7          Abnormal Aortic Aneurysms

2.2.8          Drivers of Caseloads for Cardiac Tissue Engineering

2.3       Neurological

2.3.1          Introduction

2.3.2          Stroke

2.3.3          Parkinson’s

2.3.4          Alzheimer’s

2.3.5          Epilepsy

2.3.6          Traumatic Injury

2.3.7          Peripheral Nerve Treatment

2.3.8          Multiple Sclerosis

2.3.9          Neurology Drivers

2.4       Orthopedic

2.4.1          Introduction

2.4.2          Cartilage Repair

2.4.3          Ligament Damage

2.4.4          Other Joints

2.4.5          Bone Graft Materials

2.4.6          Vertebral Disc Repair

2.5       Drivers of Orthopedic Tissue Engineering

2.6       Urological Tissue Engineering

2.6.1          Introduction

2.6.2          Incontinence

2.6.3          Drivers of Urological Tissue Engineering

2.7       Skin Tissue Engineering

2.7.1          Introduction

2.7.2          Burns

2.7.3          Pressure Ulcers

2.7.4          Diabetic Ulcers

2.7.5          Venous Ulcers

2.7.6          Plastic Surgery

2.8       Organ Replacement by Tissue Engineering

2.8.1          Introduction

2.8.2          Liver Disease

2.8.3          Kidney

2.8.4          Diabetes

2.8.5          Intestinal Tissue Engineering

2.8.6          Hematopoietic Tissue Engineering

2.8.7          Drivers of Organ Replacement Tissue Engineering

Section 3:        Technologies, Products and Markets

3.1       Overview

3.2       Cardiovascular

3.3       Neurological

3.4       Orthopedic

3.5       Urological

3.6       Skin Cell Engineering

3.7       Hematopoietic

3.8       Organ Reconstruction and Replacement

3.9       Potential for Tissue Engineering

Section 4:      Company Profiles

Profiles of 100 companies actively pursuing cell-based tissue engineering.

Appendix:  List of Companies





Exhibit 1.1  Corporate Involvement in Tissue Engineering

Exhibit 1.2:  Worldwide Sales of Tissue Engineered Products - 2001

Exhibit 1.3:  Worldwide Market for Tissue Engineered Products, 2001–2010

Exhibit 1.4:  Incidence of Diseases Targeted by Cell-Based Tissue Engineering, U.S. Incidence , 2001

Exhibit 1.5:  Timescales for Development of Tissue Engineered Products

Exhibit 1.6:  Clinical Development and Approvals (U.S.)

Exhibit 1.7:  Examples of Tissue Engineering Strategies

Exhibit 1.8:  Annual Revenues from Cell-Based Tissue Engineering Ventures in 2001

Exhibit 2.1:  Potential for Cardiovascular Tissue Engineering, Incidence s of Applicable Surgical Procedures (thousands), 2001

Exhibit 2.2:  Potential for Neurological Tissue Engineering, Incidences of Applicable Procedures (thousands), 2001

Exhibit 2.3:  Potential for Orthopedic Tissue Engineering, Incidence of Applicable Procedures (thousands), 2001

Exhibit 2.4:  Potential for Urological Tissue Engineering, Incidence of Applicable Procedures (thousands), 2001

Exhibit 2.5:  Potential For Dermal Tissue Engineering, Incidence of Applicable Procedures (thousands), 2001

Exhibit 2.6:  Potential for Organ Tissue Engineering, Incidence of Applicable Procedures (thousands), 2001

Exhibit 3.1:  Cardiovascular Cell Engineering Companies – Timescales

Exhibit 3.2:  Key Developments for Cardiovascular Repair

Exhibit 3.3:  Neurological cell engineering companies – Timescales

Exhibit 3.4:  Key Developments in Neurological Repair

Exhibit 3.5:  Orthopedic Cell Engineering Companies – Timescales

Exhibit 3.6:  Key Developments for Orthopedic Repair

Exhibit 3.7:  Urology Cell Engineering Companies – Timescales

Exhibit 3.8:  Key Developments in Urological Tissue Engineering

Exhibit 3.9:  Skin Cell Engineering Companies – Timescales

Exhibit 3.10 :  Key developments in skin tissue engineering

Exhibit 3.11:  Hematopoietic Cell Engineering Companies – Timescales

Exhibit 3.12:  Key Developments in Hematopoietic Tissue Engineering

Exhibit 3.14:  Key Developments in Organ Tissue Engineering

Exhibit 3.15:  Worldwide Market for Tissue Engineered Products, 2001–2010


This report has been superceded by the newest report on Tissue Engineering, Cell Therapy & Transplantation. Click here.


Tissue Engineering and Cell Therapy Markets, June 2002

Price: $1,950 for print or PDF; $$2,150 for both.


Order report


MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources on products and technologies on the market and under development.  Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data is used to corroborate and support assessments and projections.  Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.


 Contact: Patrick Driscoll, (949) 891-1753.

Copyright © 2002 MedMarket Diligence, LLC. All rights reserved.
Revised: 02/16/11

Our clients

Or call
+1.949.415.2609 fax

advanced medical technologies blog

Medtech Startups

Medtech financing archives


Follow us on Twitter
Follow medmarket

MedMarket Diligence Reports Coverage


Medtech Startups
Online database of recent medtech startups



Contact Us